1-2 of 2
Chris Harbron
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study

Christiane Pott, Eva Hoster, PhD, Britta Kehden, Michael Unterhalt, PhD, Michael Herold, Richard H van der Jagt, Ann Janssens, MD, Michael Kneba, Jiri Mayer, MD, Chris Pocock, PhD FRCPath FRCP, Nathalie Danesi, PhD, Günter Fingerle-Rowson, Chris Harbron, Kirsten Mundt, Robert E Marcus, Wolfgang Hiddemann
Journal: Blood
Blood (2016) 128 (22): 613.
https://doi.org/10.1182/blood.V128.22.613.613
Published: 2016
Journal Articles

Analysis of Minimal Residual Disease in Follicular Lymphoma Patients in Gadolin, a Phase III Study of Obinutuzumab Plus Bendamustine Versus Bendamustine in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Christiane Pott, MD PhD, David Belada, MD PhD, Nathalie Danesi, PhD, Günter Fingerle-Rowson, MD PhD, John Gribben, MDDSc, Chris Harbron, MPhil, Eva Hoster, PhD, Brad S Kahl, MD, Kirsten Mundt, PhD, Catherine Sebban, MD, Laurie H Sehn, MD MPH, Bruce D. Cheson, MD
Journal: Blood
Blood (2015) 126 (23): 3978.
https://doi.org/10.1182/blood.V126.23.3978.3978
Published: 2015